Loading Events

MPCCC Precision Oncology Seminars are an educational forum in which international and local guest speakers present different perspectives on the latest precision oncology research, clinical trials and treatment options.

Optimized 5 hydroxy-methyl seq of ctDNA as a biomarker of response in metastatic prostate cancer

Dr Felix Feng, Professor of Radiation Oncology, Urology, and Medicine, University of California at San Francisco

Dr Feng is a physician-scientist whose research interests include identifying biomarkers of treatment response or resistance in genitourinary cancers and developing rational approaches of targeted treatment for therapy-resistant disease.  Dr Feng’s laboratory uses high-throughput approaches to interrogate patient samples from clinical trials. His group developed the first clinical-grade biomarker panels that predict prostate cancer response to post-operative radiation (Zhao et al, Lancet Oncology 2016) and androgen deprivation (Zhao et al, JAMA Oncology 2017), and also identified a plasma-based cell-free DNA biomarker that predicts resistance to PARP1 inhibition (Quigley et al, Cancer Discovery 2017).

Event Details

Friday 27 August 1-2pm

This event will be held online via Zoom. Registrations essential.




Share This Story, Choose Your Platform!